RETRACTED ARTICLE:Analysis of Tim-3 as a therapeutic target in prostate cancer

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11409-11414

  Piao, Yong Rui ^a   Jin, Zhe Hu ^a   Yuan, Kui Chang ^a   Jin, Xuan Shun ^a  

^a Yan Bian Institute for Drug Control   (China)

Author keywords

CD4+ T cells; CD8+ T cells; Prostate cancer; Tim 3

Indexed keywords

HAVCR2 PROTEIN, HUMAN; MEMBRANE PROTEIN;

CANCER GRADING; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84939874105     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2464-1     Document Type: TB

References (17)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Ren SC, Chen R, Sun YH. Prostate cancer research in China. Asian J Androl. 2013;15:350–3.
3. Saad F, Pantel K. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer. Future Oncol. 2012;8:321–31.
4. Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, et al. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med. 2011;9:185.
5. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol. 2011;59:61–71.
6. Pontes-Junior J, Reis ST, de Oliveira LC, Sant’anna AC, Dall’oglio MF, Antunes AA, et al. Association between integrin expression and prognosis in localized prostate cancer. Prostate. 2010;70:1189–95.
7. Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012;24:213–6.
8. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318:1141–3.
9. Kikushige Y, Akashi K. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Ann N Y Acad Sci. 2012;1266:118–23.
10. Kozlowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene. 2013;525:200–7.
11. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011;32:345–9.
12. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7(2):e30676.
13. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207:2175–86.
14. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205:2763–79.
15. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245–52.
16. Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell Biol. 2013;32:648–53.
17. Han S, Feng S, Xu L, Shi W, Wang X, Wang H, et al. Tim-3 on peripheral CD4(+) and CD8(+) T cells is involved in the development of glioma. DNA Cell Biol. 2014;33:245–50.